ERBB2 and breast neoplasm: In line with these findings, serum CCL5/CXCL9 levels appear to be promising predictive biomarkers for identifying NK cell–rich breast tumors that exhibit better clinical responses to anti-HER2 therapies, underlining the therapeutic value of harnessing NK cell-mediated immune modulation.